Drug Profile
TG 6002
Alternative Names: TG-6002; VV-TK-RR-FCU1; VVWR-TK-RR-Fcu1Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Transgene
- Developer Assistance Publique Hopitaux de Paris; Transgene
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Cytosine deaminase expression stimulants; Immunologic cytotoxicity; Uracil phosphoribosyltransferase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Gastrointestinal cancer; Glioblastoma
Most Recent Events
- 14 Apr 2023 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 12 Sep 2022 Adverse events and pharmacodynamics data from a phase I/II trial in Gastrointestinal cancer released by Transgene
- 09 Sep 2022 Pharmacokinetics and safety data from a phase I/II trial in Gastrointestinal cancer presented at the European Society for Medical Oncology (ESMO-2022)